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Abstract 
K3 and K5 proteins encoded by Kaposi’s sarcoma-associated herpesvirus (KSHV) downregulate 
major histocompatibility complex class I (MHC-I) from the surface of host cells through 
ubiquitin-dependent endocytosis and degradation. The closest relative to KSHV is Herpesvirus 
saimiri (HVS) which naturally infects squirrel monkeys. The open reading frame (Orf) 12 of HVS 
shows a high structural homology to K3 and K5 proteins and thus, the functionality of Orf12 to 
downregulate MHC was tested. It was indeed found to be capable of downregulation.
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1 Background 
1.1 An Overview 
To delve into virology is to examine the many complex and clever means by which 
viruses evade the host immune response. Kaposi’s sarcoma-associated herpesvirus (KSHV), also 
known as human herpesvirus 8 (HHV8), and its primate homologue Herpesvirus saimiri (HVS) 
are prime examples to show how viruses can thrive within a host system and remain undetected 
through a number of mechanisms. 
To understand how viruses can survive in an environment designed to eliminate their 
presence, the various defenses in place within host systems must first be examined. The types of 
mechanisms involved can be placed into two broad categories; pathways which lead to lysis and 
cellular resistance through antibodies. 
Interferons (IFNs), which have a hand in a number of metabolic, hormonal and signaling 
pathways, are also a part of the body’s anti-viral immunity response. For example, IFN-alpha 
inhibits viral replication, which some viruses are able to halt by interfering at one of the many 
points in the cellular signal cascades, and some viruses can maneuver around the IFNs, like 
Epstein-Barr virus (EBV). Pertinent to this project, KSHV encodes an interferon response factor 
(IRF) which mimics the cells own IRFs to inhibit IFN function [1]. 
Another of the body’s responses to infection are chemokines, which associate with 7-
transmembrane (TM), G-protein coupled receptors. When a part of the body becomes inflamed, 
chemokines work to bring leukocytes to the point of inflammation. Similar to the evasion of 
IFNs, KSHV encodes three monocyte inflammatory proteins (MIPs) that can interject and 
competitively block chemokine receptors [1].  
One method utilized to destroy cells is the complement system which, through 
interactions between certain cell proteins and foreign proteins, leads to the activation of a cascade 
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that triggers the membrane attack complex (MAC). By forming a MAC, targeted cells and 
pathogens can be lysed [1]. 
In addition to the complement system, cells can be destroyed through apoptosis, which is 
programmed cell death used to remove unhealthy or defective cells in the system. Apoptosis can 
be triggered by a signal from either a surface receptor or an intracellular molecule. The targeted 
cells, which are usually defective, old or infected by a pathogen, are sacrificed in order to prevent 
the spread of disease and to remove cells that are functioning incorrectly. 
However, when certain viruses enter the system, the apoptotic cycle can be averted, 
giving rise to the possibility of creating an immortalized cell used to complete viral growth, an 
event which can lead to oncogenesis. KSHV is such a virus, with the ability to cause skin 
carcinomas and other lymphomas [1]. 
Yet another method employed to destroy unwanted cells is the use of natural killer (NK) 
cells found throughout the body. Their job is to find and destroy infected or defective cells. When 
a cell becomes infected, it expresses surface molecules to alert the immune system that there is a 
problem. The most important molecule for this project was major histocompatibility complex 
class I (MHC-I), which, when expressed on the cell surface, turns off the inhibition to kill of the 
NK cells, allowing them to either destroy the troubled cell or produce cytokines, which would 
work with the adaptive immune response against the cell [1]. 
KSHV has adapted to this uninviting environment of the host, finding ways to remain 
undetected as it replicates. They can avoid cytotoxic T lymphocytes (CTLs) by increasing the 
endocytosis and degradation of MHC-I surface molecules, as described above. As for B cell 
evasion, as of yet there is no data to say that KSHV directly interferes with their response, 
although indirectly KSHV’s K3 and K5, through their downregulation of the surface markers, 
may in fact limit the B cells’ ability to present antigens, which would mimic the effect of MHC-1 
downregulation, and consequently slow T helper cell costimulation [1]. 
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The main focus of this project was to work with KSHV’s protein K3 (sometimes referred 
to in the literature as MIR1) and HVS’s open reading frame 12 (Orf12), respectively, 
characterizing how Orf12 interacts with MHC-I surface proteins on host cells. Without MHC-I 
expression, along with downregulation of ICAM-1 and B7.2 by K5 (MIR2, [7,10,12]), NK and 
CTL cells are essentially blind to the difference between a healthy and infected cell [2]. 
Another important aspect to the downregulation of MHC-I, besides being a viral evasion 
strategy, is the question of exactly how this downregulation occurs. Ubiquitin has been found to 
play an important role in this process, as K3, K5 and presumably Orf12 are E3 ubiquitin ligases 
[15]. Orf12 is thought to also be an E3 because of its high homology with other members of the 
MARCH protein family (Figure 1), which contain a plant homeodomain/leukemia-associated 
protein domain (PHD/LAP) at the N terminus, which includes a RING domain with a conserved 
series of cysteines and a histidine (C4HC3) involved in a zinc finger motif followed by a two TM 
(transmembrane) domain [4,9]. 
 
Figure 1: Homology within the K3 Protein Family (adapted from [4]) 
 
Also of note in Figure 1, besides the C4HC3 motif (highlighted red in the figure), is the 
tryptophan (W) to the right of C5, which all the members of this family show except for HVS 
Orf12, which has a histidine (H). The above amino acid sequence is part of the zinc binding 
finger, as seen in figure 2 below. 
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Figure 2: Structure of Orf12 
 
The E3s associate with a specific substrate, in this case MHC-I, using their RING domain 
and their role is to facilitate the transfer of ubiquitin from an E2 enzyme to the substrate. Once 
tagged, MHC-I molecules are endocytosed and trafficked to the cell’s lysosome, localizing to the 
trans-Golgi network (TGN) and late endocytic compartments before degradation [3,6,8,9]. 
Experiments performed on this trafficking pathway suggest that while the RING domain is 
responsible for internalization, the motifs highlighted below (Figure 3) in red and green in the C-
terminus are essential for the directing of MHC-I to the lysosome from the TGN [1,9]. 
 
Figure 3: K3 and K5 Protein Motif Diagram (adapted from [9]) 
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Figure 4: Endocytosis and Degradation of MHC-I 
 
While studying the ubiquitination of MHC-I, researchers have also found that K3 does 
not require MHC-I to have a lysine in its intracytoplasmic tail in order for endocytosis to occur, 
as would be expected [14]. Instead, a cysteine is required, which in this case allows for 
ubiquitination structurally identical to that which is normally seen with K5 using lysine [15]. 
Orf12 should also be characterized based on this finding. 
 
1.2 Project Purpose  
I was given the task of working with a virus related to KSHV, Herpesvirus saimiri 
(HVS), whose natural host is the South American squirrel monkey [5]. When these primates are 
exposed to HVS, the virus is non-pathogenic, despite high virus titers. However, when introduced 
to other new world primates, they almost always develop fatal lymphomas. By comparing the 
differences and similarities between KSHV and HVS, we can better understand the mechanisms 
at work for pathogenesis and oncogenesis. 
KSHV utilizes one of its proteins, K3, to downregulate MHC-I proteins on the surface of 
host cells. The homologue of K3 in HVS is the protein Orf12 (Figure 5), which is structurally 
very similar and may be functionally inactive. Besides having a truncated C-terminus, Orf12 has 
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a histidine at a key point in its PHD/LAP domain where K3 has a tryptophan, as was shown in 
figure 1 above. 
 
Figure 5: Schematic of Orf12 and K3 
 
K3 and Orf12 belong to a family of E3 ubiquitin ligases, which means they are 
responsible for substrate specificity during ubiquitination. Because the PHD/LAP domain is 
thought to contain the active site for ubiquitination for K3, an Orf12 H->W point mutation was 
designed because every other homologous protein in the K3 family expresses a tryptophan where 
Orf12 expresses a histidine. 
As described above, K3 is known to utilize ubiquitin to tag MHC-I and send it to the cells 
own lysosome, although the exact pathway has yet to be determined. The literature suggests that 
K3 acts to upregulate endocytosis of surface MHC-I molecules, and then directs them to the TGN 
before being sent to the lysosome for degradation [9]. The wild type (wt) and point mutant (mut) 
Orf12 constructs were packaged into micelles through the use of transfectin, and through 
membrane fusion the constructs were put into the cells in vitro. Flow cytometry was then used to 
look for downregulation of MHC-I, and confocal microscopy was used to see localization of 
Orf12 within the cell. 
In addition to the construction of the point mutant, the wt and mut DNA were used as 
PCR templates to form chimeras of Orf12 and K3 as shown below in Figure 6 (Orf12 blue, K3 
red). Unfortunately for this project, time permitted that only chimeras one and two could be made 
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and tested, although the PCR primers have already been assembled for the remaining 
combinations. 
 
Figure 6: Schematic of Chimeras and Point Mutant 
 
Because the TM domain of K3 is known to be responsible for localization, the first two 
chimeras include this domain and swap out the K3 PHD/LAP for the wt and mut Orf12. Using 
this construct, the protein should localize as expected from K3 experiments, but now a targeting 
of MHC-I by Orf12 should be observed. When assembled, chimeras three and four will determine 
whether or not the C-terminal portion of Orf12 affects downregulation of MHC-I, and chimera 
six will use the PHD/LAP of K3, which is known to be functional for downregulation, and the 
TM and C-terminal domain of Orf12 to characterize localization of Orf12. 
The phenotypic assays performed included Western blotting, which was used to visualize 
protein expression with size markers, flow cytometry, which quantitates protein expression in 
cells with the use of antibody staining, and confocal microscopy, which shows localization of the 
protein within the cells. 
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2 Methods  
2.1 Protocols, Equipment and Techniques 
During the three months spent working in the lab I learned how to perform a number of 
techniques and procedures. Some I had been exposed to from lab courses during school, but most 
I had only read about in research articles. In this section I will describe the techniques I learned to 
perform and how I was able to utilize them. Each was critical for the completion of my research 
project. 
2.2 Polymerase Chain Reaction (PCR) 
PCR is a technique used to amplify specific portions of DNA. Primers are designed and 
added to a reaction along with the template DNA, dNTPs, water and a magnesium-containing 
buffer. The tubes are put into the PCR machine, which controls the temperature needed and the 
duration of each cycle. A typical program is an initial denaturation for two minutes at 94ºC, 
followed by 30 cycles of the following three steps: 
1. 94ºC 10 seconds (denaturation) 
2. 52ºC 1 minute (primer annealing) 
3. 72ºC 1 minute (primer extension)  
For this project I designed and utilized thirteen original primers to amplify the whole and 
parts of the Orf12 gene, and parts of the K3 gene. The list of primers and their sequences can be 
found in the appendix and a schematic of their alignment with the genes amplified is shown 
below in Figure 7. Primer names in parentheses represent primers used to clone into the pEGFP-
N1 vector while the rest are for the pTracer EF/V5-His A vector. 
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Figure 7: PCR Primer Placement on Orf-12 and K3. 
 
First I amplified the entire Orf12 using the viral HVS DNA as a template and M1 and M2 
as the primers. Next came the Orf12 H->W point mutant, which used primers M1, M4, M2 and 
M6. The mutant had to be done in two rounds of PCR, one to amplify the introduced mutation 
and the left half of the open reading frame and an overlap of the mutation with the right half of 
the open reading frame, then a second PCR to combine the two halves. The chimeras also had to 
be done in two rounds, the first round to amplify the Orf12 and K3 portions, then the second to 
stitch the two halves together to form one chimeric protein. 
2.3 DNA Purification 
To purify the PCR products, both before and after restriction digestion, and to purify the 
vectors after digestion, the Qiagen “QIAquick gel extraction kit” was used according to the 
manufacturer’s protocol.  PCR product and buffer were spun in a spin column and washed with 
EtOH solution then eluted with warm water. 
  10 
  
At one point in the project I had to purify bands of DNA from an agarose gel following 
electrophoresis, which entailed cutting out the bands with a razor blade, putting the gel into an 
eppendorf tube with buffer, melting the gel in the fifty-six degree Celsius water bath and then 
proceeding with the normal purification protocol of spinning, washing with EtOH and eluting 
with water. 
2.4 Agarose Gel Electrophoresis 
DNA concentration and restriction digest analyses were run often on either 1.0% or 1.5% 
agarose gels in 1X TBE buffer. A 1kB DNA ladder (Gibco BRL) was used as a size marker to 
locate the Orf12 fragment (~500bp). The electrophoresis was performed at 200V, 400mA and for 
twenty minutes usually, then the DNA stained with ethidium bromide was detected using a UV 
transilluminator. 
2.5 DNA Restriction Digests 
Restriction digests allowed me to see whether or not my DNA fragment was inserted into 
the vector. I designed my PCR primers for cloning into the pTracer-EF/V5-His A vector using the 
restriction sites EcoRI and SpeI. This expression construct should produce the Orf12 protein 
fused to the V5 and His epitope tag to allow detection of the protein. Restriction digests using 
EcoRI and SpeI were incubated in the EcoRI buffer (New England Biolabs). For the EGFP-N1 
vector I used the EcoRI and BamHI sites for cloning, and digests were also incubated in the 
EcoRI buffer. The original primer design for the EGFP-N1 vector used BglII and BamHI, 
however because problems developed with those two enzymes interacting with each other I was 
advised to make a new primer using EcoRI instead of BglII. This expression construct should 
result in the production of a fusion protein of Orf12 with green fluorescent protein (GFP). 
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2.6 DNA Cloning 
Two vectors were used to clone into E. coli; pTracer-EF/V5 His A was the standard 
vector used for expression, and pEGFP-N1 was used for localization assays. Diagrams of each 
vector can be found in the appendix. First a ligation reaction was performed to combine the cut 
and purified vector with the cut and purified DNA fragment using ligation buffers and T4 DNA 
ligase. The ligated DNAs were then introduced into competent bacteria on ice. 
After thirty minutes, the cells were heat shocked at forty-two degrees Celsius, and then 
recovered with S.O.C medium in the thirty-seven degree water bath for another thirty minutes. 
The transformed bacteria were then plated on an appropriately antibiotic LB agar plate along with 
a negative control plate (the ligation included water instead of insert). The plates were put into a 
thirty-seven degree incubator overnight and usually ten colonies were chosen to be grown up in 
LB broth for plasmid DNA minipreps. 
2.7 Plasmid DNA Mini- and Maxipreps 
Miniprep cultures were grown in 3mL LB media with the appropriate antibiotic, which 
was ampicillin for the Tracer vector and kanamycin for the EGFP vector. Colonies were picked 
from the cloning plates and following overnight incubation in medium, the DNA was extracted 
using the Marligen rapid purification kit. The DNA was then digested to see which colonies 
actually contained my insert, and from there sequencing reactions of promising clones were set 
up and sent to the Yale sequencing facility. 
Once a clone with the correct sequence was determined, a maxiprep culture was grown in 
500mL LB medium overnight. From this culture a high concentration of the correct plasmid DNA 
would be produced. Maxipreps of the wt and mut Orf12 were important for this project because 
Orf12 had never been cloned before so there is no stock of it. Also, to generate the chimeras these 
two sources of DNA would be used as templates during the PCR reactions instead of using up the 
entire stock of whole viral DNA. 
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2.8 Tissue Culture 
For this project a 293T cell line was used. I was responsible for maintaining at least one 
culture flask, which I used to make six well plates when needed for transfections and I split them 
one to seven twice a week. The medium used was DMEM supplemented with ten percent FBS, 
glutamine, streptomycin and penicillin. 
Transfections involved mini- or maxiprepped DNA, and as controls empty vector 
(negative) and vector with an inserted gB gene (positive). For minipreps, 8uL of DNA was 
arbitrarily chosen for transfections because of their low concentrations, however for the controls 
and for maxiprepped DNA 4ug was used. The method of transfection used transfectin, which 
forms micelles around the DNA, which then fuse to the phospholipid bilayers of the 293T cells, 
enabling them to deposit the DNA inside the cells. 
While working with the tissue cultures, I had to become proficient at sterile technique 
and working in a biosafety cabinet. This skill included limiting the amount of time that containers 
were open and cells were exposed to air, not putting culture flask and media bottle caps on the 
surface inside the hood, and opening sterile plates, media containers and sterile pipettes behind 
the air flow and glass shield. 
2.9 Western Blotting 
Western blots are used to characterize proteins by visualizing their expression. Cell 
lysates are loaded onto an SDS polyacylamide gel along with a size marker, and then the gel is 
transferred using a semidry transfer blotter (BioRad) to a membrane. Antibodies specific to the 
protein of interest or epitope tags are added, followed by incubation with a secondary antibody 
that recognizes the first antibody, which can then be visualized using detection chemicals that 
cause fluorescence (enhanced chemiluminescence, ECL). 
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Because Orf12 is about twenty kD, I used a fifteen percent resolving solution to cast my 
acrylamide gels. I harvested my transfected 293T cells using PBS, then spun them down and 
resuspended the pellets in laemmli buffer. After boiling and vortexing the samples I loaded them 
into the wells along with a marker and filled any unused wells with laemmli buffer for equal salt 
distribution in the electric field. 
The electrophoresis was performed at 150mA for one hour, and then the proteins were 
transferred onto membrane filter, which took about forty minutes. After the transfer the 
membrane was put into a five percent milk solution in PBS Tween for one hour, then the primary 
antibody was added for one hour and secondary antibody for forty-five minutes with PBS Tween 
washes in between. For pTracer expression constructs,  an anti-V5 primary and anti-mouse 
secondary were used, and for pEGFP expression constructs an anti-GFP primary and anti-rabbit 
secondary were used. For these assays the secondary antibodies were preadsorbed to human 
antibodies. 
2.10 Flow Cytometry 
Flow cytometry is a technique used to quantitate how much protein is being expressed by 
cells. Paraformaldehyde-fixed cells are analyzed in the instrument in a single cell suspension, 
then hit with a laser to determine forward scatter (size), side scatter (granularity) and fluorescence 
(bound antibody presence). For this project, the amount of MHC-I expressed on the surface of 
293T and COS-7 cells was measured using an antibody for MHC-I called W6/32 conjugated to a 
red fluorophor. 
The cells, which were 293T and also COS-7 (primate), were grown in six well plates. For 
the first round of flow cytometry, the first well was left untransfected as a control, the second 
well was transfected with empty vector, the third well was transfected with K3 and the fourth 
with K5 as positive controls for the downregulation of MHC-I, and the fifth and sixth had my 
maxiprepped Orf12 wt and Orf12 mut DNA. 
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The cells were harvested with PBS plus EDTA, which separates the cells from the plate 
and from each other, and then they were screened through a mesh filter to ensure that the cells 
were not clumped together. They were added to a tube filled with 10% FBS DMEM to replace the 
calcium lost from the addition of PBS plus EDTA. The cells were stained with the appropriate 
antibody, pelleted, washed with PBS, pelleted again, then fixed with paraformaldehyde. 
At the flow cytometer, the controls were used to set the gate parameters according to the 
cell populations and to make sure that the red (MHC-I) and green (GFP) signals did not cross into 
one another. Each sample was read until a fixed number of events had passed across the laser, and 
the mean fluorescence of the samples was recorded. 
2.11  Confocal Microscopy 
Confocal microscopy allows us to look at localization of proteins within cells. The 
microscope used for this project viewed cells in two dimensions instead of three in as small as 0.1 
micron slices in order to best see where in the cell Orf12 localizes. COS-7 cells transfected with 
my clones were grown on the microscope slides, then fixed with paraformaldehyde after being 
stained with ethidium bromide as a nuclear cellular marker. The slides were then examined under 
the microscope, using a laser to make the stain and the protein fluoresce. In this case, the protein 
fused to GFP fluoresced green and the marker was red.  
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3 Results  
The first major result of this project was the production of DNA stocks for Orf12 wt and 
Orf12H->W mutant in both pTracer-EF/V5 His A and pEGFP-N1 for future experiments. The 
Orf12 DNAs were amplified by PCR, and ligated into the plasmids. The correct insert size was 
determined by agarose gel electrophoresis (Figure 8) and the sequences were analyzed and found 
to be completely correct. 
 
 
Figure 8: Restriction Digest Showing the Correct Size Orf12 wt Insert 
Lane-1 represents a 1kB DNA ladder (Gibco BRL), and lane-2 denotes Orf12 wt in pTracer digested with 
EcoRI and SpeI restriction enzymes to release the insert. 
 
Western blotting was performed several times but only one protein, chimera 2 (mut #13) 
was able to be detected, as seen below in Figure 9. 
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Figure 9: Western Blot Showing Chimera 2 (mut #13) Fused to GFP 
 
The DNAs were transfected into 293T and COS-7 cells, and through the use of flow 
cytometry, Orf12 wt and mut were analyzed and found to indeed be able to downregulate surface 
MHC-I, and the mut seemed to work more efficiently than wt (Figure 9). Chimeras one and two 
were also characterized using flow cytometry and, as expected from the Orf12 wt and mut data, 
were able to downregulate MHC-I as well. Most samples were run alongside empty vector, using 
K3 and K5 as controls. K5 is known to be less efficient than K3 at downregulating MHC-I. 
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Figure 10: Flow Cytometry Analysis of MHC-I Expression in Transfected 293T and COS-7 Cells 
The Y-axis denotes MHC-I staining, and the X-axis represents GFP staining. 
 
In Figure 10 above, empty pTracer vector shows no downregulation, K3 shows 
relatively high downregulation, K5 shows slightly less downregulation, and Orf12 wt and 
mut show slightly less than K5, but there is still a significant difference in these from 
empty vector.
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pEGFP pEGFP ORF12-K3 mut #12 pEGFP ORF12-K3 mut #13 pEGFP ORF12 pEGFP ORF12 mut
18.0 9.7 9.6 7.8
GFP
MHC I
7.5
 
Figure 11: Flow Cytometry Analysis of MHC-I Expression in Cells Transfected with EGFP Chimera 
Two (mut, two clones) and Orf12 wt and mut 
 
 
pTracer gB pTracer ORF12 mut pTacer ORF12 wt pTracer ORF12-K3 wt
9.2 10.8 13.0 12.6
GFP
MHC I
 
Figure 12: Flow Cytometry Analysis of MHC-I Expression in Cells Transfected with Tracer Orf12 
wt and mut (try two) and Chimera One (wt) 
 
 In figures 12 and 17, the pTracer gB control had a surprisingly low transfection 
efficiency, as its fluorescence should be higher than the samples’. Therefore the three samples are 
better considered among themselves and not compared to the control, as all performed as 
expected relative to one another. Also of note is the closeness of data between the two chimera 
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muts (#12 and #13), which were run together because both their sequencing data were correct, 
and between Orf12 wt and Chimera 1 (wt). 
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Figure 13: Flow Cytometry Data, 293T GMC 
 
 
low G Green All high G
pTracer 12.19 12.66 11.45 15.84
K3 6.89 7.15 7.17 11.04
K5 8.58 9.11 7.85 12.6
Orf12wt 9.3 10.06 8.53 14.18
Orf12mut 9.56 9.71 8.2 14.13  
Table 1: Flow Cytometry Data, 293T GMC 
 
 In the above chart and table (and following charts and tables), one of the key 
points to look at is how Orf12 mut always seems to be slightly more efficient at 
downregulating MHC-I than Orf12 wt. These data will have to be replicated to see if a 
pattern truly exists. 
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293T Flow Cytometry Data (LMC)
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Figure 14: Flow Cytometry Data, 293T LMC 
 
 
low G Green All high G
pTracer 12.16 12.62 11.1 16.55
K3 6.97 7.23 7.02 10.88
K5 8.24 8.63 7.5 12.02
Orf12wt 9.45 10.14 8.03 14.26
Orf12mut 9.02 9.25 7.66 13.27  
Table 2: Flow Cytometry Data, 293T LMC 
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293T and COS-7 Flow Cytometry Data
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Figure 15: Flow Cytometry Data, 293T and COS-7 
 
 
293T COS-7
GMC LMC GMC LMC
pTracer 29.29 27.38 75.38 75.68
K3 12.45 13.45 17.14 44.74
K5 23.06 20.98 44.98 45.04
Orf12wt 14.65 13.12 52.71 49.09
Orf12mut 14.12 11.61 39.54 38.69  
Table 3:  Flow Cytometry Data, 293T and COS-7 
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Flow Cytometry Data EGFP-N1
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Figure 16: pEGFP Flow Cytometry Data 
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Figure 17: pTracer Flow Cytometry Data 
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4 Conclusions  
The completion of this project has begun the scientific characterization of the Orf12 
protein of HVS. From the data collected, Orf12 wt, Orf12 H->W point mutant and chimeras one 
and two can downregulate MHC-I from the cell surface of transfected 293T  or COS-7 cells. This 
project also hoped to look at localization of the proteins inside host cells using immunostaining 
and confocal microscopy, however the correct conditions for the slides were difficult to meet and 
time restrictions allowed for only a couple tries before the project ended. 
According to the flow cytometry data, Orf12 wt can downregulate MHC-I, however the 
Orf12 mut seems to downregulate MHC-I more efficiently. This data brought up an interesting 
question, because while other proteins in the same family as Orf12, namely K3 and K5, use a 
tryptophan as the connecting point for the E2 enzyme, Orf12 has a histidine. Assuming that the 
histidine would need to be changed to a tryptophan in order to produce functionality, we were 
surprised to find that both the wt and mut downregulated MHC-I. 
Assuming the findings from this single FACS experiment duplicate, these data may 
indicate that the Orf12 protein, when mutated to mimic the key tryptophan residue of other family 
members, has surrounding domains that facilitate a stronger interaction with E2 than K3 or K5.  
Or alternatively, further research into the nature of E2s may demonstrate that while other 
members of the K3 family of E3 proteins use the E2 UbcH7, Orf12 could possibly break away 
from the pattern and use Rad6, an E2 normally involved with DNA replication corrections [11]. 
 
Figure 18: E2 Binding Sites (adapted from [11]) 
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Because 293T and COS-7 cells were used, there is the possibility that these cell lines 
have more UbcH7 than Rad6 E2s, which would explain why the point mutant would appear more 
efficient at downregulation of MHC-I. The next step will be to examine Orf12 wt and mut in the 
presence of either UbcH7 or Rad 6 to further characterize this interaction. 
As far as Western blotting and confocal microscopy, the proteins and cells were 
uncooperative. Expression of Orf12 was difficult to visualize on Western blots, the most likely 
possibilities being its small size (~18.5kD), low translation rate within cells, instability, 
aggregation or degradation inside cells. However expression could be seen under a fluorescence 
scope and flow cytometry data confirms that the proteins are present because of downregulated 
MHC-I expression. At the very end of the project chimera 1 (wt) was finally visualized by 
Western blot, probably because this protein is twice as large as Orf12. Confocal microscopy also 
posed a problem, as the cells used for the transfections did not adhere very well to the slides and 
thus could not be visualized correctly. 
 Unfortunately time did not permit for me to perform thorough phenotypic assays for all 
of the chimeras, although just as my time in the lab ended correct clones were constructed for 
chimeras one and two. The chimeric fragments were not inserting well into the vectors and 
needed several repeats in order to get the few clones acquired. The data collected and chimeras 
eventually formed as a result of this project are the beginning of a continuing characterization that 
will hopefully result in a publication. Another will use the rest of the primers I developed to better 
characterize Orf12 beyond my preliminary findings, so the final result of my time in the lab was 
to setup for future experiments. 
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5 Appendix   
5.1 HVS Orf12 amino acid sequence: 
MSSIQKKCLICCNIGEEELLQACDCPSRVHHTCLQSHIQCFKSSHCTFCEKKYKIMVMCNS
LKKCSSPVLEQANWIVLCVCVSTLLCILCILLDICLTIRLWQSSVLCYEVYNTFYFLVLCG
TFSIAFYLAAWYDIFFEFHSLCSFIWNLKKISQSYPCEASKNALKIL* 
 
 
5.2 KSHV K3 amino acid sequence: 
 MEDEDVPVCWICNEELGNERFRACGCTGELENVHRSCLSTWLTISRNTACQICGVVYNT
RVVWRPLREMTLLPRLTYQEGLELIVFIFIMTLGAAGLAAATWVWLYIVGGHDPEIDHV
AAAAYYVFFVFYQLFVVFGLGAFFHMMRHVGRAYAAVNTRVEVFPYRPRPTSPECAVE
EIELQEILPRGDNQDEEGPAGAAPGDQNGPAGAAPGDQDGPADGAPVHRDSEESVDEAA
GYKEAGEPTHNDGRDDNVEPTAVGCDCNNLGAERYRATYCGGYVGAQSGDGAYSVSC
HNKAGPSSLVDILPQGLPGGGYGSMGVIRKRSAVSSALMFH* 
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5.3 pTracer EF/V5-His A Vector Map: 
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5.4 pTracer EF/V5-His A Multiple Cloning Site: 
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5.5 pEGFP-N1 Vector Map: 
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5.6 PCR Primers: 
M1:  AA  ACT  AGT  GCC  ACC  ATG  AGC  AGT  TTT  CAA  AAG  AAA  TG 
                     SpeI             Kozak 
M2:  AA  GAA  TTC  CAG  TAT  TTT  TAA  TGC  ATT  TTT  GCT  C 
                    EcoRI 
M3: GAG  CAA  CTG  ATT  GTT  TTT  ATT  TTC  ATT  ATG  AC 
 
M4:  GAA  AAT  AAA  AAC  AAT  CAG  TTG  CTC  TAG  AAC  AGG  CGA  GC 
 
M5:  TG  CAA  AGT  TGG  ATT  CAG  TGT  TTA  AAA  TCA  TCT  CAT  TG 
 
M6:  AA  ACA  CTG  AAT  CCA  ACT  TTG  CAA  GCA  TGT  ATG  G 
 
M7:  G  GGT  CTG  GAA  GCT  AAC  TGG  ATA  GTT  TTA  TGT  G 
 
M8:  T  CCA  GTT  AGC  TTC  CAG  ACC  CTC  CTG  GTA  AG 
 
M9:  GT  GCG  TTT  TTC  TTT  GAG  TTT  AAG  AGC  TTA  TGT  AG 
 
M10:  CTT  AAA  CTC  AAA  GAA  AAA  CGC  ACC  CAA  CCC  AA 
 
M11:  AAA  AGA  TCT  GCC  ACC  ATG  AGC  AGT  TTT  CAA  AAG  AAA  TG 
                          BglII           Kozak 
M12:  A  GGA  TCC  CCC  AGT  ATT  TTT  AAT  GCA  TTT  TTG  CTC 
                   BamHI 
M13:  AA  GAA  TTC  GCC  ACC  ATG  AGC  AGT  TTT  CAA  AAG  AAA  TG 
                      EcoRI           Kozak 
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5.7 K3 Structure Prediction: 
 
5.8 Orf12 Structure Prediction: 
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